Taking On Challenges And Growing? – Gilead Sciences, Inc. (GILD)

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Stocks Info

This NASDAQ-listed company operates within the Drug Manufacturers – General industry segment, falling under the Healthcare sector. The current market capitalization of Gilead Sciences, Inc. is $80.61B. A total of 5.56 million shares were traded on the day, compared to an average of 7.08M shares.

In the most recent transaction, GILEAD SCIENCES, INC. bought 485,250 shares of GILD for 0.76 per share on Apr 02 ’24. After the transaction, the 10% Owner now owns 7,345,473 company shares. In a previous transaction on Apr 01 ’24, Parsey Merdad sold 2,000 shares at 72.96 per share. GILD shares that Chief Medical Officer owns now total 96,304.

Among the insiders who sold shares, Parsey Merdad disposed of 8,230 shares on Feb 29 ’24 at a per-share price of $72.74. This resulted in the Chief Medical Officer holding 92,706 shares of GILD after the transaction. In another insider transaction, Parsey Merdad sold 2,000 shares at $73.18 per share on Feb 28 ’24. Company shares held by the Chief Medical Officer now total 100,936.


The income generated by dividends is an indication that a company is improving its financial position, which is why investors prefer companies paying dividends. Gilead Sciences, Inc. pays an annual dividend of $3.02, resulting in a dividend yield of 4.67%, and it has a price to earnings (P/E) ratio of 180.37. GILD’s most recent ex-dividend date was 6/14/2024 when it declared a $0.77 quarterly dividend that was paid in cash on 6/27/2024. Previously, the company paid the dividend on 3/28/2024 with an ex-dividend date of 3/14/2024. The GILD stock dividend was $0.77 per share in cash.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, GILD has a high of $87.86 and a low of $62.07.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. GILD’s latest balance sheet shows that the firm has $6.52B in Cash & Short Term Investments as of fiscal 2021. There were $26.70B in debt and $11.61B in liabilities at the time. Its Book Value Per Share was $14.08, while its Total Shareholder’s Equity was $21.06B.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for GILD is Buy with a score of 3.83.

Most Popular

Related Posts